These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 10816702)
1. The stage is set for the diffusion of positron emission tomography (PET) in oncology. Morris JG Med J Aust; 1999 Nov; 171(10):527-8. PubMed ID: 10816702 [No Abstract] [Full Text] [Related]
2. Positron emission tomography (PET): experience with a large-field-of-view three-dimensional PET scanner. Hicks RJ; Binns DS; Fawcett ME; Ware RE; Kalff V; McKenzie AF; Zalcberg JP; Peters LJ Med J Aust; 1999 Nov; 171(10):529-32. PubMed ID: 10816703 [TBL] [Abstract][Full Text] [Related]
3. Fluoro-2-deoxy-glucose positron emission tomography in oncology: are we there yet? Khafagi FA Intern Med J; 2001; 31(1):3-4. PubMed ID: 11478354 [No Abstract] [Full Text] [Related]
4. An approach to demonstrating cost-effectiveness of diagnostic imaging modalities in Australia illustrated by positron emission tomography. Miles KA Australas Radiol; 2001 Feb; 45(1):9-18. PubMed ID: 11259966 [TBL] [Abstract][Full Text] [Related]
5. The clinical use of PET--where are we now? Cook GJ Br J Radiol; 2001 May; 74(881):399-401. PubMed ID: 11388986 [No Abstract] [Full Text] [Related]
6. Advances in FDG PET probes in surgical oncology. Essner R; Daghighian F; Giuliano AE Cancer J; 2002; 8(2):100-8. PubMed ID: 11999944 [TBL] [Abstract][Full Text] [Related]
7. [Positron emission tomography and the Hungarian PET program]. Trón L Orv Hetil; 2002 May; 143(21 Suppl 3):1235-40. PubMed ID: 12077904 [TBL] [Abstract][Full Text] [Related]
8. Positron-emitting radiopharmaceuticals: how safe are they? Silberstein EB Cancer Biother Radiopharm; 2001 Feb; 16(1):13-5. PubMed ID: 11279793 [No Abstract] [Full Text] [Related]
9. [Positron emission tomography in the Netherlands: need to expand the capacity]. Comans EF; Smit EF Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1817-9. PubMed ID: 12382364 [TBL] [Abstract][Full Text] [Related]
10. Guest editorial: the conception of FDG-PET imaging. Alavi A; Reivich M Semin Nucl Med; 2002 Jan; 32(1):2-5. PubMed ID: 11839067 [No Abstract] [Full Text] [Related]
14. Current status of positron emission tomography in oncology. Scott AM Intern Med J; 2001; 31(1):27-36. PubMed ID: 11478353 [TBL] [Abstract][Full Text] [Related]
15. [2002 Standards, Options and Recommendations for the use of [18F]-FDG (PET-FDG) in cancerology]. Bourguet P; Bull Cancer; 2003 Feb; 90 Spec No():S1-109. PubMed ID: 12744225 [No Abstract] [Full Text] [Related]
16. Measurement of tumor response using [18F]-2-fluoro-2-deoxy-D-glucose and positron-emission tomography. Lammertsma AA J Clin Pharmacol; 2001 Jul; 41(S7):104S-106S. PubMed ID: 11452713 [No Abstract] [Full Text] [Related]
17. Positron emission tomography (PET) in diagnostic oncology: is it a necessary tool today? Price P Eur J Cancer; 2000 Apr; 36(6):691-3. PubMed ID: 10762740 [No Abstract] [Full Text] [Related]
18. [The role of positron emission tomography with C18-Fluorodeoxyglucose in clinical oncology]. Granov AM; Tiushin LA; Tlostanova MS; Kostenikov NA; Ryzhkova DV; Savello VE; Stanzhevskiĭ AA Vopr Onkol; 2003; 49(5):563-73. PubMed ID: 14682126 [TBL] [Abstract][Full Text] [Related]
19. [Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology]. Soepenberg O Ned Tijdschr Geneeskd; 2000 Oct; 144(41):1979-80. PubMed ID: 11048563 [No Abstract] [Full Text] [Related]